ArticleJournal of clinical pathology1998
Retinoblastoma (RB1) gene product expression in breast carcinoma. Correlation with Ki-67 growth fraction and biopathological profile.
Article in Journal of clinical pathology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 37 citations in OpenAlex.
- Patients with Invasive Lobular Carcinoma Show a Significant Increase in IRS-4 Expression Compared to Infiltrative Ductal Carcinoma-A Histopathological Study.Medicina (Kaunas, Lithuania) · 2022Article
- Ki67 and progesterone receptor status predicts sensitivity to palbociclib: a real-world study.Annals of translational medicine · 2021Article
- Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience.Diagnostics (Basel, Switzerland) · 2020Article
- Network and data integration for biomarker signature discovery via network smoothed T-statistics.PloS one · 2013Article
- Targeting Rb inactivation in cancers by synthetic lethality.American journal of cancer research · 2011Article
- RB1CC1 together with RB1 and p53 predicts long-term survival in Japanese breast cancer patients.PloS one · 2010Article
- Cellular quiescence in mammary stem cells and breast tumor stem cells: got testable hypotheses?Journal of mammary gland biology and neoplasia · 2009Review
- Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically.The American journal of surgical pathology · 2009Article
- Tailoring to RB: tumour suppressor status and therapeutic response.Nature reviews. Cancer · 2008Review
- Epithelial cell proliferation contributes to airway remodeling in severe asthma.American journal of respiratory and critical care medicine · 2007Article
- The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer.The Journal of clinical investigation · 2007Article
- Article
- Suppressor of cytokine signalling 2 (SOCS-2) expression in breast carcinoma.Journal of clinical pathology · 2005Article
- An immunohistochemical study of retinoblastoma gene product in normal, premalignant and malignant tissues of the uterine cervix.The Malaysian journal of medical sciences : MJMS · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo investigate the expression of retinoblastoma protein (pRb) in invasive breast tumours and compare its expression with the major biopathological prognostic indicators to identify more aggressive subgroups. MATERIAL: Archival paraffin embedded tissues from 153 consecutive primary breast carcinomas.
methodspRb, Ki-67, and oestrogen receptor/progesterone receptor proteins were identified by immunohistochemistry and score values were recorded by image cytometric analysis; p53 and EGFr expression was also evaluated.
resultspRb scores correlated strongly with proliferation activity as determined by Ki-67 staining. Positive relations were also observed between pRb scores, tumour size, nuclear and histological grade, and oestrogen receptor/progesterone receptor content, while abnormal p53 accumulation was not associated with pRb expression. Among the high proliferating carcinomas it was possible to identify 13 cases with loss of pRb expression.
conclusionspRb expression paralleled proliferative activity in the majority of breast carcinomas examined, suggesting that in these cases the protein behaves normally in regulating the cell cycle. Conversely in cases with loss of pRb immunostaining, the combined expression of specific highly aggressive factors (EGFr and p53 expression, oestrogen receptor/progesterone receptor negative status, and high K67) seems to characterise a more aggressive phenotype showing growth advantage and cellular "progression" rather than significant nodal involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.